Related Experiment Videos
Maintaining cognitive function in Alzheimer disease: how effective are current treatments?
1Department of Psychiatry, University of Rochester Medical Center, New York, USA. Pierre_Tariot@URMC.Rochester.edu
Alzheimer Disease and Associated Disorders
|October 24, 2001
Summary
This study shows that galantamine, an acetylcholinesterase inhibitor, can stabilize cognitive decline in patients with mild-to-moderate Alzheimer disease (AD). This treatment may help maintain cognitive function, offering significant benefits for both patients and their caregivers.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Cognitive impairment is a primary characteristic of Alzheimer disease (AD), significantly impacting daily function and increasing caregiver burden.
- Cholinergic system deficits are implicated in AD pathogenesis, making cholinergic enhancement a therapeutic target.
- Stabilizing cognitive decline, measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), is a crucial treatment goal.
Purpose of the Study:
- To evaluate the long-term efficacy of galantamine in stabilizing cognitive function in patients with mild-to-moderate Alzheimer disease.
- To compare the effects of galantamine with placebo on cognitive decline over a 12-month period.
- To explore the dual mechanism of galantamine, including acetylcholinesterase inhibition and nicotinic receptor modulation.
Main Methods:
- A 12-month study involving patients with mild-to-moderate AD, including a 6-month double-blind, placebo-controlled phase followed by a 6-month open-label extension.
- Cognitive function was assessed using the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Mini-Mental State Examination (MMSE).
- Galantamine's effects were compared to placebo, with analysis of ADAS-cog and MMSE score changes from baseline.
Main Results:
- Galantamine treatment resulted in no significant change in mean ADAS-cog scores from baseline at the 12-month study endpoint.
- This indicates a stabilization of cognitive function in patients receiving galantamine over the study duration.
- Conventional acetylcholinesterase inhibitors have shown similar stabilization effects on ADAS-cog scores up to 40 weeks in other studies.
Conclusions:
- Cholinergic treatments, specifically galantamine, demonstrate the potential to stabilize cognitive decline in individuals with mild-to-moderate Alzheimer disease.
- Maintaining cognitive function can significantly improve the quality of life for AD patients and reduce the demands on caregivers.
- Galantamine's dual mechanism of action may contribute to its efficacy in managing cognitive symptoms of AD.